The natural history and control of cytomegalovirus infection following allogeneic stem cell transplantation

被引：0
|
作者：
Gamett, G. [1 ]
Boeckh, M. [2 ]
Einsele, H. [3 ]
Emery, V. [4 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Wurzburg, Wurzburg, Germany
[4] Royal Free & Univ Coll Med Sch, London WC1E 6BT, England
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S237 / S238
页数：2
相关论文
共 50 条
  • [31] Risk factors for cytomegalovirus infection of 79 allogeneic hematopoietic stem cell transplantation patients
    Tan, Y.
    Liu, X.
    Zhao, Y.
    Su, L.
    Liu, Y.
    Gao, S.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S406 - S406
  • [32] Cytomegalovirus infections following reduced-intensity allogeneic stem cell transplantation.
    Nakamura, R
    Cohen, S
    Palmer, J
    Hawkins, G
    Tegtmeier, B
    Spielberger, R
    Smith, E
    Ito, J
    O'Donnell, MR
    Smith, D
    Zaia, JA
    Forman, SJ
    BLOOD, 2004, 104 (11) : 617A - 617A
  • [33] Adoptive cellular therapy for cytomegalovirus following allogeneic stem cell transplantation: Toxicity and efficacy
    Peggs, KS
    Verfuerth, S
    Chow, C
    Thomson, K
    Goldstone, AH
    Linch, DC
    Mackinnon, S
    BLOOD, 2004, 104 (11) : 59A - 59A
  • [34] High dose acyclovir for cytomegalovirus infection prophylaxis after allogeneic stem cell transplantation
    Iannella, E.
    Lori, A. P.
    Torelli, G. F.
    Milano, F.
    Capobianchi, A.
    Lucarelli, B.
    Malandruccolo, L.
    Valle, V.
    Arleo, E.
    Martino, P.
    Foa, R.
    Gentile, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 103 - 103
  • [35] Cytomegalovirus (CMV) infection in allogeneic non-myeloablative stem cell transplantation recipients
    Chandrasekar, P
    King, R
    Dansey, R
    Akhtar, A
    Mellon-Reppen, S
    Alangaden, G
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 43 - 43
  • [36] Valganciclovir for the prophylaxis of early cytomegalovirus (CMV) infection after allogeneic stem cell transplantation
    Bachier, C
    Shaughnessy, P
    Wall, D
    Grimley, M
    Carrum, G
    Freytes, C
    Callander, N
    Walsh, T
    LeMaistre, CF
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 90 - 91
  • [37] Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience
    Gezici, Baris
    Gunes, Ajda Ersoy
    Soyer, Nur Akad
    Saydam, Guray
    Tobu, Mahmut
    Sahin, Fahri
    Vural, Filiz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S517 - S518
  • [38] QuantiFERON-cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
    Thompson, Grace
    Boan, Peter
    Purtill, Duncan
    Cooney, Julian
    Cannell, Paul
    Wright, Matthew
    John, Mina
    TRANSPLANT INFECTIOUS DISEASE, 2022, 24 (02)
  • [39] CYTOMEGALOVIRUS INFECTION IN HEMATOLOGICAL PATIENTS FOLLOWING AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION
    Piukovics, K.
    Terhes, G.
    Deak, J.
    Borbenyi, Z.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6114 - 6114
  • [40] Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study
    Junghanss, C
    Boeckh, M
    Carter, RA
    Sandmaier, BM
    Maris, MB
    Maloney, DG
    Chauncey, T
    McSweeney, PA
    Little, MT
    Corey, L
    Storb, R
    BLOOD, 2002, 99 (06) : 1978 - 1985
12345